Dermatitis Herpetiformis

In a patient with a symmetric, intensely pruritic papulovesicular or excoriated eruption on the elbows, knees, buttocks, scalp, or other extensor surfaces, obtain a biopsy of normal-appearing skin immediately adjacent to an active lesion for direct immunofluorescence (DIF). Granular IgA deposits in the papillary dermis, at papillary tips, or along the dermal-epidermal junction are diagnostic of dermatitis herpetiformis (DH). Perilesional uninvolved skin is the preferred specimen because lesional tissue may not retain the diagnostic IgA pattern. BMJ+3BMJDiagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology | GutPubMedDermatitis herpetiformis in an adolescent patient - PMCPubMedImproving the Diagnosis of Dermatitis Herpetiformis Using the Intraepithelial Lymphogram - PMCPubMedThe diagnosis and treatment of dermatitis herpetiformis - PMC

Routine histopathology can support the clinical impression when it shows a subepidermal blister with neutrophilic microabscesses in dermal papillae, but it does not replace DIF. A histologically compatible biopsy without granular IgA should prompt reconsideration of other immunobullous disorders rather than empiric labeling as DH. ScienceDirect+1ScienceDirectDermatitis Herpetiformis - an overview | ScienceDirect TopicsPubMedThe diagnosis and treatment of dermatitis herpetiformis - PMC

DIF is reported to have sensitivity and specificity close to 100% when performed from uninvolved perilesional skin. A positive DIF establishes DH even when serum celiac antibodies are absent, because some patients with DH lack circulating celiac-specific antibodies. BMJ+1BMJcoeliac enteropathies in adults: the Paris consensusPubMedThe diagnosis and treatment of dermatitis herpetiformis - PMC

DH is the specific cutaneous manifestation of celiac disease/gluten-sensitive enteropathy. Most, but not all, affected patients have circulating anti-tTG antibodies and duodenal villous atrophy; approximately 70% have villous atrophy, while others have celiac-like inflammatory intestinal changes. Therefore, absence of diarrhea, weight loss, or malabsorption symptoms should not alter the need for a lifelong gluten-free diet after diagnostic confirmation. BMJ+2BMJDermatitis herpetiformis - Symptoms, diagnosis and treatment | BMJ Best PracticeGastroenterologyEpidemiology, Presentation, and Diagnosis of Celiac DiseasePubMedImproving the Diagnosis of Dermatitis Herpetiformis Using the Intraepithelial Lymphogram - PMC

For a patient with biopsy-proven DH, a duodenal biopsy is generally unnecessary to diagnose celiac disease. Consider gastrointestinal evaluation when the diagnosis remains equivocal, when DIF is unavailable or nondiagnostic, or when another cause of villous atrophy is being considered. In equivocal villous atrophy with negative celiac serology, HLA-DQ2/DQ8 testing can help: negative HLA typing excludes seronegative celiac disease, whereas positive typing is not diagnostic because these haplotypes occur in 30% to 40% of Caucasian populations. BMJ+1BMJcoeliac enteropathies in adults: the Paris consensusPubMedThe diagnosis and treatment of dermatitis herpetiformis - PMC

Assess enteropathy-related consequences at baseline and during follow-up with complete blood count, ferritin, folate, vitamin B12, calcium, alkaline phosphatase, aminotransferases, thyroid-stimulating hormone with thyroid hormone testing, and serum glucose. Anti-TG2, endomysial antibody, or deamidated gliadin peptide testing can support assessment of dietary adherence, but serology cannot substitute for a structured dietary interview. BMJBMJDiagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology | Gut

Prescribe a lifelong strict gluten-free diet (GFD) for every patient with confirmed DH and arrange dietary counseling at initiation. The GFD is the treatment of choice because it treats the gluten-driven enteropathy and, over time, reduces skin disease and medication dependence. In a 212-patient experience, 78 of 133 patients who followed the diet achieved complete rash clearance with diet alone, and many remaining adherent patients reduced medication requirements. BMJ+1BMJDermatitis herpetiformis - Symptoms, diagnosis and treatment | BMJ Best PracticeNEJMGluten-Free Diets and Dermatitis Herpetiformis | NEJM Clinician

Set expectations that cutaneous control may remain incomplete during the first months of a GFD. Dapsone is appropriate as bridging therapy for active pruritus and lesions during this interval, whereas dietary nonadherence is a likely contributor to recurrent activity. Patients who lapse more than once weekly were classified as effectively following a normal diet in the long-term cohort. BMJ+1BMJDermatitis herpetiformis - Symptoms, diagnosis and treatment | BMJ Best PracticeNEJMGluten-Free Diets and Dermatitis Herpetiformis | NEJM Clinician

Review medications, supplements, and dietary products for gluten exposure when rash activity persists despite reported adherence. Dapsone should not be presented as an alternative to dietary treatment: it improves itch but has no effect on small-intestinal inflammation. BMJ+1BMJTransition from childhood to adulthood in coeliac disease - GutScienceDirectDermatitis herpetiformis: Part II. Diagnosis, management, and prognosis - ScienceDirect

Use oral dapsone when severe pruritus or ongoing skin lesions require rapid suppression while a strict GFD takes effect. Dapsone is described as the most effective drug for controlling DH skin lesions and pruritus during the first months after dietary initiation; a usual starting dose of 100 mg/day is reported. Do not escalate beyond source-supported dosing on the basis of this reference alone. BMJ+1BMJDermatitis herpetiformis - Symptoms, diagnosis and treatment | BMJ Best PracticeScienceDirectDermatitis Herpetiformis - an overview | ScienceDirect Topics

Before and during dapsone treatment, obtain blood testing sufficient to detect hematologic toxicity and actively evaluate symptoms compatible with hemolysis or methemoglobinemia. Dapsone-associated hemolytic anemia, methemoglobinemia, leukopenia, and hypersensitivity syndrome are clinically important toxicities; patients with low G6PD activity are particularly vulnerable to hemolysis and methemoglobinemia. ScienceDirect+1ScienceDirectDermatitis Herpetiformis - an overview | ScienceDirect TopicsWolters KluwerDapsone Induced Methemoglobinemia and Hemolysis... : Indian Journal of Dermatology

If cyanosis, dizziness, nausea, vomiting, unexplained low pulse oximetry, or dark-brown blood develops after dapsone exposure, stop dapsone and evaluate urgently for methemoglobinemia and hemolysis. Methylene blue may aggravate hemolysis in G6PD deficiency; management therefore requires confirmation of the patient’s G6PD status and toxicology-informed treatment selection. Wolters KluwerWolters KluwerDapsone Induced Methemoglobinemia and Hemolysis... : Indian Journal of Dermatology

Schedule follow-up during the initial treatment period to document lesion and pruritus response, review the GFD with a structured dietary history, and monitor dapsone adverse effects. Once disease is stable and the patient can manage the diet, transition to annual follow-up. BMJ+1BMJDermatitis herpetiformis - Symptoms, diagnosis and treatment | BMJ Best PracticeBMJDiagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology | Gut

At annual review, assess full blood count, ferritin, serum folate, vitamin B12, calcium, alkaline phosphatase, aminotransferases, thyroid status, and serum glucose. Use celiac antibody testing as an adjunct to—not a substitute for—dietary assessment. Persistent rash should trigger an adherence review and reconsideration of diagnostic accuracy if the original DIF was not definitive. BMJBMJDiagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology | Gut

Escalate diagnostic evaluation when the clinical phenotype is atypical, DIF is negative or unavailable, or findings suggest a competing immunobullous disease. In patients with equivocal intestinal pathology and negative celiac serology, a diagnostic gluten challenge has been suggested at at least 10 g gluten daily for 6 to 8 weeks, although dose and duration are not standardized; this approach is for resolving uncertainty, not routine monitoring of established DH. BMJBMJcoeliac enteropathies in adults: the Paris consensus